Atomoxetine - Strattera brand: Discontinuation

Discontinuation Active

Eli Lilly are discontinuing all strengths of their Strattera brand atomoxetine.

Affected product

Eli Lilly are discontinuing the following products:

Atomoxetine (Strattera brand)

  • 10 mg caps - Pharmacode: 2181568
  • 18 mg caps - Pharmacode: 2181576
  • 40 mg caps - Pharmacode: 2181592

Atomoxetine listing in the Schedule(external link)

Alternative product

People can still access atomoxetine in all the same strengths. The Apo-Atomoxetine brand is already listed and remains available. 

APO-Atomoxetine contains the same active ingredients in the same amounts as Strattera brand. It works in the body the same way. Medsafe have evaluated the product to ensure it meets standards of safety and quality. They  have assessed that it works as well as Strattera. 

This discontinuation is a global decision made by Eli Lilly.  

Key dates

April 2023 – Strattera brand stock will be depleted.

1 November 2023 – Strattera brand will be de-listed from the Pharmaceutical Schedule.

Who to contact

If you have any questions about the funding of atomoxetine, email enquiry@pharmac.govt.nz